Area of research
Immunology · Biotechnology
Research interest
Research focused on Immunotherapy and Clinical trial, with related work in Glioblastoma, Tumor-infiltrating lymphocytes, Somatic hypermutation. Notable publications include 'Comprehensive Analysis of Hypermutation in Human Cancer', 'T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma', and 'Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy'.
Glioblastoma and the immune milieu: overview and focus on immune checkpoint blockade
Current landscape of immunotherapy for CNS tumors
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA
Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression
A review of glioblastoma immunotherapy
Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank
Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery
Cancers from Novel <i>Pole</i> -Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade
Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Comprehensive Analysis of Hypermutation in Human Cancer
Genomic landscape of high-grade meningiomas
Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling
Erratum: Genomic landscape of high-grade meningiomas
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy
Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1
Emerging Insights into Barriers to Effective Brain Tumor Therapeutics